ReviewWorld journal of gastrointestinal pharmacology and therapeutics2026
Precision immunotherapy in oesophageal squamous cell carcinoma: Molecular pathogenesis and checkpoint inhibitor response prediction.
Review in World journal of gastrointestinal pharmacology and therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Oesophageal squamous cell carcinoma (ESCC) remains a significant global health challenge due to its aggressive nature and poor prognosis. Recent advances in immunotherapy, particularly immune checkpoint inhibitors (ICIs), have revolutionized treatment paradigms. This review comprehensively examines the molecular pathogenesis of ESCC, highlighting key oncogenic pathways and immune evasion mechanisms. Furthermore, it explores the evolving landscape of biomarkers and predictive models for ICI response, emphasizing the critical role of precision immunotherapy in tailoring treatment strategies. A deeper understanding of these molecular and immunological underpinnings is essential for optimizing patient selection, overcoming resistance, and ultimately enhancing therapeutic efficacy in ESCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.